Abbott Laboratories

New York Stock Exchange
Back to all articles
Bullish +65

Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), GE Healthcare Technologies Inc (GEHC)

AI-generated analysis

📈 TD Cowen analyst Josh Jennings maintains a Buy rating on Abbott Laboratories with a $115.00 price target.

📊 Robert W. Baird initiated coverage on Abbott Laboratories with a Buy rating and a $121.00 price target.

🎯 Abbott Laboratories holds a Strong Buy consensus with an average price target of $117.95, implying 25.5% upside.

🏥 Jefferies analyst Matthew Taylor maintains a Buy rating on GE Healthcare Technologies Inc at $90.00.

💰 BTIG assigned a Buy rating to GE Healthcare Technologies Inc with a $75.00 price target.

🚀 Canaccord Genuity analyst Edward Nash maintains a Buy rating on Rani Therapeutics Holdings at $5.00.

📉 H.C. Wainwright maintained a Buy rating on Rani Therapeutics Holdings with an $11.00 price target.

🔍 The Street consensus for Rani Therapeutics implies 986.3% upside from current levels.

📝 TipRanks aggregates analyst data to track performance and momentum in the healthcare sector.

Bullish Signals
  • TD Cowen, Robert W. Baird, Jefferies, BTIG, Canaccord Genuity, and H.C. Wainwright have all issued Buy ratings on Abbott Laboratories, GE Healthcare Technologies Inc, or Rani Therapeutics Holdings.
  • Abbott Laboratories has a Strong Buy consensus with an average price target of $117.95, representing 25.5% upside from current levels.
  • Rani Therapeutics Holdings has a Strong Buy Street consensus with an average price target of $7.50, implying 986.3% upside from current prices.
  • Analysts covering these healthcare stocks cite strong sector optimism and specific company fundamentals supporting their bullish ratings.
Full Analysis
Healthcare sector analysts have expressed bullish sentiment toward Abbott Laboratories (ABT), GE Healthcare Technologies Inc (GEHC), and Rani Therapeutics Holdings (RANI). TD Cowen analyst Josh Jennings reaffirmed a Buy rating on Abbott, setting a price target of $115.00, while Robert W. Baird initiated coverage with a Buy rating and a $121.00 target. The consensus for Abbott remains Strong Buy with an average price target of $117.95, suggesting approximately 25.5% upside from recent trading levels. Analysts also maintain positive outlooks for GE Healthcare Technologies Inc and Rani Therapeutics Holdings. Jefferies analyst Matthew Taylor kept a Buy rating on GEHC with a $90.00 price target, supported by BTIG's recent Buy assignment at $75.00. For Rani Therapeutics, Canaccord Genuity and H.C. Wainwright both issued Buy ratings with targets of $5.00 and $11.00 respectively, reflecting a strong Street consensus that implies significant potential upside from current market prices. The article aggregates analyst ratings and price targets provided by TipRanks, highlighting the collective optimism for these healthcare equities. While specific financial metrics like revenue or earnings are not detailed in this text, the focus remains on the strength of analyst recommendations and the implied valuation gaps between current stock prices and consensus targets.